Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia
- 1 February 2008
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 35, S1-S17
- https://doi.org/10.1053/j.seminoncol.2007.12.002
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell linesInvestigational New Drugs, 2006
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- MicroRNA expression profiles classify human cancersNature, 2005
- A microRNA polycistron as a potential human oncogeneNature, 2005
- Survival benefit with imatinib mesylate therapy in patients with accelerated‐phase chronic myelogenous leukemia—Comparison with historic experienceCancer, 2005
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988